English
中文Pipeline
Products under development
| Treatment field |
Pipeline | source of technology | Mechanism | Target indication |
Preclinical studies |
IND Declaration |
Clinical Trial PhaseⅠ |
Clinical Trial Phase Ⅱ |
Clinical Trial Phase Ⅲ |
rights interests |
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Metabolic diseases | PB-119 | Independent R D | a long-acting GLP-1 receptor agonist | type 2 diabetes mellitus | Global |
 |
|||||
| Metabolic diseases | PB-2301 | Independent R D | a long-acting GLP-1/GIP receptor agonist | type 2 diabetes mellitus | Global |
|
|||||
| Metabolic diseases | PB-2309 | Independent R D | a long-acting GLP-1/GIP/GCPreceptor agonist | type 2 diabetes mellitus |
|
||||||
| Metabolic diseases | PB-718 | Independent R D | a dual agonist that activates both the GLP-1 receptor and the glucagon receptor | nonalcoholic fatty liver disease | Global |
|
|||||
| Metabolic diseases | PB-119 | Independent R D | a long-acting GLP-1 receptor agonist | overweight or obesity | Global |
|
|||||
| Metabolic diseases | PB-718 | Independent R D | a dual agonist that activates both the GLP-1 receptor and the glucagon receptor | overweight or obesity | Global |
|
|||||
| Gastrointestinal diseases | PB-1902 | Independent R D | the only oral opioid receptor antagonist for the treatment of opioid-induced constipation (OIC) | opioid-induced constipation | Global |
|
|||||
| other Metabolic diseases | PB-722 | Independent R D | GCG receptor agonist | a novel drug for congenital hyperinsulinemia | Global |
|
|||||
